MK6482-022

About this trial

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

Patient Profile

This trial is for patients with Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy

Where’s this trial being run?

Beaumont Hospital and Cork University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: MK6482-022
Number: 21-37
Full Title:

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

Principal Investigator: Prof Ray McDermott
Type: Industry Sponsored
Sponsor:

MSD

Recruitment Started: Global: March 2022
Ireland: July 2022
Global Recruitment Target: 1600
Ireland Recruitment Target: 15